news
An innovative drug for the immunotherapy of triple-negative breast cancer registered in Russia
The Russian Ministry of Health has registered the PD-1 inhibitor Areima® (INN: camrelizumab) for the treatment of triple-negative breast cancer (TNBC)
Petrovax Pharm supports a documentary project about the lives of people with rare diseases
Neoadjuvant immunotherapy shifts the treatment paradigm for triple-negative breast cancer
From pregnancy preparation to vaccination: experts outline priorities in children's health at the forum "Russia and the World: Trends in Healthy Longevity"
Clinical trials of a quadrivalent meningococcal vaccine completed in Russia
Early Diagnosis and Timely Treatment: expert-defined priorities in the management of Fabry Disease presented at the “Orphan Diseases” сongress
Petrovax Pharm to launch exports of medicinal products to South Africa
Petrovax Pharm presents immuno-oncology innovation at opening of new Moscow City Oncology Hospital No. 62 Complex in Skolkovo
A Study Evaluating Longidaza® Published in Urologia Journal: Combination Treatment Reduced the Risk of Chronic Prostatitis Recurrence Nearly Fourfold
